EC Number |
Inhibitors |
Structure |
---|
2.3.1.B41 | 3-morpholinosydnonimine |
- |
|
2.3.1.B41 | 4-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxaline |
- |
|
2.3.1.B41 | 4-phenyl-5-((3-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline |
- |
|
2.3.1.B41 | 4-phenyl-5-(phenylsulfonyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline |
- |
|
2.3.1.B41 | 5-(phenylsulfonyl)-4-(pyridin-3-yl)-4,5-dihydropyrrolo[1,2-a]quinoxaline |
- |
|
2.3.1.B41 | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide |
i.e. EX-527. 0.2 mM, 56% inhibition, substrate: Ac-RYQ(N6-acetyl)K-7-amido-4-methylcoumarin |
|
2.3.1.B41 | Cl316,243 |
a lipolysis drug, interfers with SIRT6 |
|
2.3.1.B41 | H2N-AK-(N(epsilon)-thioacetyl-)lysine-LM-COOH |
moderate potent inhibitor |
|
2.3.1.B41 | H2N-HK-(N(epsilon)-thioacetyl-)lysine-LM-COOH |
moderate potent inhibitor |
|
2.3.1.B41 | luteolin |
30% inhibition at 0.1 mM |
|